XEN1101 seems protected and efficient for the therapy of focal-onset seizures (FOSs), in accordance with outcomes of a part 2b research revealed on-line Oct. 9 in JAMA Neurology.
Jacqueline A. French, M.D., from the New York College Complete Epilepsy Middle in New York Metropolis, and colleagues evaluated the efficacy and security of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener, for the therapy of FOS. The evaluation included 285 sufferers who had been randomly assigned (2:1:1:2) to obtain XEN1101 25, 20, or 10 mg, or placebo with meals as soon as day by day for eight weeks.
The researchers reported that therapy with XEN1101 was related to seizure discount in a strong dose-response method. From baseline, the median% discount in month-to-month FOS frequency was 52.8% for 25 mg, 46.4% for 20 mg, and 33.2% for 10 mg. Remedy-emergent opposed occasions had been just like these of generally prescribed antiseizure drugs.
“The outcomes of this research help the additional medical improvement of XEN1101 for the therapy of FOSs,” the authors write. “The findings of this research recommend that XEN1101 has the potential to deal with the unmet want for a therapy with a novel mechanism of motion for sufferers.”
Extra info:
Jacqueline A. French et al, Efficacy and Security of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy, JAMA Neurology (2023). DOI: 10.1001/jamaneurol.2023.3542
2023 HealthDay. All rights reserved.
Quotation:
Novel potassium channel opener protected, efficient for adults with focal epilepsy (2023, October 14)
retrieved 14 October 2023
from https://medicalxpress.com/information/2023-10-potassium-channel-safe-effective-adults.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
